Clinical trials: Chronic Nausea
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Malignant Neoplasm, Nausea
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer.
- Conditions
- Malignant Neoplasm, Nausea, Vomiting
- Trial name
- NCT03040726
- Testing
- Netupitant, Palonosetron, Palonosetron Hydrochloride
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Patients With Gastroparesis Who Have Failed Standard Therapy
Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
To provide oral domperidone to patients between the ages of 18 and 60 years of age, according to the investigator's judgment, a prokinetic effect is needed for the relief of severe gastroparesis.
- Trial name
- NCT01711918
- Testing
- Domperidone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ron Schey
Functional Dyspepsia
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar…
- Trial name
- NCT06217393
- Testing
- Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets
- Where
- 19 sites in Armenia, Malaysia and 3 more
- Volunteers
- 564 people
- Sponsor
- Abbott
Chronic Unexplained Nausea and Vomiting, Gastroparesis
Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
The hypothesis of this pilot study is that nVNS will result in relief of nausea by modulation of vagal nerve activity. nVNS is the first non-invasive, handheld medical device applied on the side of the neck and sends gentle…
- Trial name
- nVNS (NCT04857281)
- Testing
- nVNS (gammaCore)
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Johns Hopkins University
Pain, Nausea
Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain
The investigators are conducting this study to find out if intravenous (injected through the vein) infusion of lidocaine and ketamine administered with general anesthesia is as effective as a paravertebral block in lessening pain…
- Trial name
- NCT00720330
- Testing
- ropivacaine, Lidocaine/Ketamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Cleveland Clinic
Hematologic Diseases, Acute Myelogenous Leukemia
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
The goal of this clinical research study is to compare the effectiveness of receiving a combination of ondansetron and aprepitant to receiving ondansetron alone in helping to prevent nausea and/or vomiting in patients with Acute…
- Conditions
- Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT00954941
- Testing
- Ondansetron, Aprepitant
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Gastroparesis
Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether 4 weeks of treatment with aprepitant will improve nausea as compared with placebo in patients with symptoms of chronic…
- Trial name
- APRON (NCT01149369)
- Testing
- Aprepitant
- Where
- 8 sites in United States
- Volunteers
- 126 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Advanced Cancer
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
The purpose of this study is to evaluate the use of olanzapine for the treatment of cancer patients with chronic nausea and/or vomiting unrelated to chemotherapy or radiation in a randomized placebo-controlled pilot trial.
- Trial name
- NCT03137121
- Testing
- Olanzapine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00795769
- Testing
- ondansetron, survey administration, management of therapy complications
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute